Please do not leave this page until complete. This can take a few moments.
Marlborough drugmaker RXi Pharmaceuticals is shifting its business strategy to focus on the development of the most potentially lucrative of its three treatment areas -- the immuno-oncology program, the company announced Tuesday.
RXi is working on using its RNAi treatment to replace antibody treatments, a potentially $100-billion market. The company was largely focused on developing treatment for dermatology (skin care) and ophthalmology (eye care) until it acquired Cambridge drugmaker MirImmune, Inc. in 2017 to look at immuno-oncology to treat cancer.
In a statement on Tuesday, RXi President and CEO Geert Cauwenbergh cited positive clinical results from its dermatology study validating the safety and efficacy of the company’s self-delivering RNAi compounds’ ability to treat cancer in humans.
“These outcomes coupled with robust preclinical results in our immuno-oncology program, further affirm the company's focused development path,” Cauwenbergh said.
The company plans to partner or out-license its dermatology and ophthalmology franchises. Proceeds from those transactions will be used to fund the company’s renewed focus on immuno-oncology, the company said.
Both of those programs include preclinical and clinical-stage assets covered by a robust intellectual property estate, the company said.
By focusing on its immuno-oncology program, Cauwenbergh said the company could change the paradigm in cancer treatments.
He added feedback from leading cancer centers, business partners and investors act as an endorsement of the new strategy.
“It is our goal to develop novel immuno-oncology treatments to benefit patients as well as our long-term shareholders and business partners,” he said.
CORRECTION: A previous version of this story said RXi was looking to replace the antibiotic market. In actuality, the company is working to replace the antibody market.
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments